Tag Archives: vaccine-grade protein

A Gun to their Head: the Exclusive Vaccine Club

International tensions over access to Covid-19 vaccines have intensified as supply hiccups disrupt mass rollouts of shots. But trade experts warn that restrictions on vaccine exports risk making a bad situation worse. That’s because the world’s major vaccine producers rely on each other for the essential ingredients to manufacture vaccines through a web of cross-border supply chains in complex chemicals, fatty acids and glass vials. If governments restrict vaccine exports, they risk retaliation from other members of this exclusive club of vaccine makers, who could withhold vital supplies, squeezing production just when it is needed most.

These supply chains stretch across the world, drawing in producers of basic chemicals that provide critical ingredients as well as the pharmaceutical powerhouses that make the vaccines. The  U.S. , the  European Union  and  China  are among a handful of territories that produce vaccine ingredients and final vaccines for the entire world. More than half of global vaccines and of key vaccine ingredients come from the  U.S.  and  EU . These 12 countries and the EU make up the “Vaccine Club”—producers that make both the key ingredients as well as final vaccines

The members of the vaccine club, though, source on average 88.3% of the imported ingredients used in vaccine production from other club members, according to economists led by Simon Evenett, professor of international trade and economic development at the University of St. Gallen in Switzerland, who have mapped trade flows between the world’s major vaccine producers. Limiting vaccine exports to another major producer would therefore risk retaliatory action that could undermine production, threatening the mass vaccination drives that are the key to ending the pandemic, Prof. Evenett said. “Everyone has a gun to each other’s heads,” he said.

Excerpts from The Covid-19 Vaccine Club: How the World’s Biggest Producers Depend on Each Other, WSJ, May 1, 2021

The Next Pandemic and the US Military

U.S. military forces are the front line of U.S. national security, but as a globally deployed force they are also on the front line of any new pathogen-based health threat that may emerge [including also due to biological warfare]. As overall human activity pushes ever further into previously undeveloped territory, the likelihood of exposure to new pandemic diseases increases.  The 2009 Army Posture Statement, cites a World Health Organization estimate of between 20 and 50 percent of the world’s population being affected if a pandemic were to emerge. WHO forecasts “it may be six to nine months before a vaccine for a pandemic virus strain becomes available.” In a separate report on pandemic influenza, the WHO describes several challenges to producing sufficient volumes of vaccine using current, egg-based protein-production technology, including the likelihood that two doses per person could be required due to the absence of pre-existing immunity.

In short, the potential for a pandemic exists and current technological limitations on defensive measures put the health and readiness of U.S. military forces at risk. A technological solution to increase the speed and adaptability of vaccine production is urgently needed to match the broad biological threat.

DARPA’s Blue Angel program seeks to demonstrate a flexible and agile capability for the Department of Defense to rapidly react to and neutralize any natural or intentional pandemic disease. Building on a previous DARPA program, Accelerated Manufacture of Pharmaceuticals, Blue Angel targets new ways of producing large amounts of high-quality, vaccine-grade protein in less than three months in response to emerging and novel biological threats. One of the research avenues explores plant-made proteins for candidate vaccine production.“Vaccinating susceptible populations during the initial stage of a pandemic is critical to containment,” said Dr. Alan Magill, DARPA program manager. “We’re looking at plant-based solutions to vaccine production as a more rapid and efficient alternative to the standard egg-based technologies, and the research is very promising.”

In a recent milestone development under Blue Angel, researchers at Medicago Inc. produced more than 10 million doses (as defined in an animal model) of an H1N1 influenza vaccine candidate based on virus-like particles (VLP) in one month….“The results we’ve achieved here with plant-based production of vaccines represent both significant increase in scale and decrease in time-to-production over previous production capabilities in the same time period. The plant-made community is now better positioned to continue development and target FDA approval of candidate vaccines,” Magill said. “Once the FDA has approved a plant-made vaccine candidate, the shorter production times of plant-made pharmaceuticals should allow DoD to be much better prepared to face whatever pandemic next emerges.”

DARPA Makes 10 Million Strides in the Race to Contain a Hypothetical Pandemic, July 25, 2012